{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:04:38Z","timestamp":1776744278094,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.chest.2023.05.024","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:03:57Z","timestamp":1685030637000},"page":"860-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Hypertonic Saline on Lung Function as Add-on Treatment in People With Cystic Fibrosis Receiving Dornase Alfa"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-0037","authenticated-orcid":false,"given":"Athanasios G.","family":"Kaditis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6791-661X","authenticated-orcid":false,"given":"James","family":"Acton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Kheirandish-Gozal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarah","family":"Ner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-3398","authenticated-orcid":false,"given":"Rebekah","family":"Nevel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8195-6036","authenticated-orcid":false,"given":"David","family":"Gozal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9179-4325","authenticated-orcid":false,"given":"Adrienne","family":"Ohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.chest.2023.05.024_bib1","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2023.05.024_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.chest.2023.05.024_bib3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.chest.2023.05.024_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2023.05.024_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2023.05.024_bib6","first-page":"CD001127","article-title":"Dornase alfa for cystic fibrosis","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9290","key":"10.1016\/j.chest.2023.05.024_bib7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.chest.2023.05.024_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2023.05.024_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcf.2018.08.004","article-title":"Investigating the effects of long-term dornase alfa use on lung function using registry data","volume":"18","author":"Newsome","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.chest.2023.05.024_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2023.05.024_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2023.05.024_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.chest.2023.05.024_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2011-200953","article-title":"Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study","volume":"67","author":"Taylor-Robinson","year":"2012","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.chest.2023.05.024_bib14","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ppul.24377","article-title":"Regional variations in longitudinal pulmonary function: a comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"246","key":"10.1016\/j.chest.2023.05.024_bib15","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","volume":"11","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat"},{"issue":"4","key":"10.1016\/j.chest.2023.05.024_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1536867X0400400403","article-title":"Controlling for time-dependent confounding using marginal structural models","volume":"4","author":"Fewell","year":"2004","journal-title":"Stata J"},{"issue":"3","key":"10.1016\/j.chest.2023.05.024_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcf.2020.08.004","article-title":"Dornase alfa and rate of lung function decline in European patients with cystic fibrosis: a retrospective registry cohort study","volume":"20","author":"McKone","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.chest.2023.05.024_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jcf.2021.02.004","article-title":"Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis","volume":"20","author":"Voldby","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chest.2023.05.024_bib19","first-page":"742","article-title":"Therapeutic effect of nebulized hypertonic saline for muco-obstructive lung diseases: a systematic review and meta-analysis with trial sequential analysis","volume":"69","author":"Zhang","year":"2021","journal-title":"J\u00a0Invest Med"},{"issue":"3","key":"10.1016\/j.chest.2023.05.024_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A\u00a0controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.chest.2023.05.024_bib21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2012.5214","article-title":"Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial","volume":"307","author":"Rosenfeld","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.chest.2023.05.024_bib22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2023.05.024_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(21)00546-4","article-title":"The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial","volume":"10","author":"Tiddens","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2023.05.024_bib24","first-page":"CD001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"9","author":"Wark","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.chest.2023.05.024_bib25","article-title":"Post hoc power analysis: is it an informative and meaningful analysis?","volume":"32","author":"Zhang","year":"2019","journal-title":"Gen Psychiatr"},{"issue":"7","key":"10.1016\/j.chest.2023.05.024_bib26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ppul.25371","article-title":"How abnormal is the normal? Clinical characteristics of CF patients with normal FEV1","volume":"56","author":"Cohen-Cymberknoh","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.chest.2023.05.024_bib27","doi-asserted-by":"crossref","first-page":"1900748","DOI":"10.1183\/13993003.00748-2019","article-title":"Structural determinants of long-term functional outcomes in young children with cystic fibrosis","volume":"55","author":"Turkovic","year":"2020","journal-title":"Eur Respir J"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223007833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223007833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T01:28:25Z","timestamp":1727486905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223007833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0012369223007833"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.05.024","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Hypertonic Saline on Lung Function as Add-on Treatment in People With Cystic Fibrosis Receiving Dornase Alfa","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}